Altimmune Inc said on Tuesday that its obesity drug helped reduce patients' weight by about 10% on average in a mid-stage trial, but concerns over the drug's safety sent the company's shares tumbling nearly 40% in premarket trading.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,